JP2024520676A5 - - Google Patents

Info

Publication number
JP2024520676A5
JP2024520676A5 JP2023574474A JP2023574474A JP2024520676A5 JP 2024520676 A5 JP2024520676 A5 JP 2024520676A5 JP 2023574474 A JP2023574474 A JP 2023574474A JP 2023574474 A JP2023574474 A JP 2023574474A JP 2024520676 A5 JP2024520676 A5 JP 2024520676A5
Authority
JP
Japan
Prior art keywords
seq
nos
nucleic acid
sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031818 external-priority patent/WO2022256437A1/en
Publication of JP2024520676A publication Critical patent/JP2024520676A/ja
Publication of JP2024520676A5 publication Critical patent/JP2024520676A5/ja
Pending legal-status Critical Current

Links

JP2023574474A 2021-06-02 2022-06-01 Nr4a3欠損免疫細胞及びその使用 Pending JP2024520676A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163195956P 2021-06-02 2021-06-02
US63/195,956 2021-06-02
US202263365023P 2022-05-19 2022-05-19
US63/365,023 2022-05-19
PCT/US2022/031818 WO2022256437A1 (en) 2021-06-02 2022-06-01 Nr4a3-deficient immune cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2024520676A JP2024520676A (ja) 2024-05-24
JP2024520676A5 true JP2024520676A5 (cg-RX-API-DMAC10.html) 2025-06-09

Family

ID=82308458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574474A Pending JP2024520676A (ja) 2021-06-02 2022-06-01 Nr4a3欠損免疫細胞及びその使用

Country Status (8)

Country Link
US (1) US12679879B2 (cg-RX-API-DMAC10.html)
EP (1) EP4347826A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024520676A (cg-RX-API-DMAC10.html)
KR (1) KR20240027676A (cg-RX-API-DMAC10.html)
AU (1) AU2022286947A1 (cg-RX-API-DMAC10.html)
CA (1) CA3177712A1 (cg-RX-API-DMAC10.html)
TW (1) TW202306577A (cg-RX-API-DMAC10.html)
WO (1) WO2022256437A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
US20260083846A1 (en) * 2022-05-19 2026-03-26 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2024064958A1 (en) * 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) * 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025059663A1 (en) * 2023-09-14 2025-03-20 Outpace Bio, Inc. Anti-exhaustion compositions and methods of use thereof
CN120818493A (zh) * 2024-04-15 2025-10-21 毕诺济(上海)生物技术有限公司 基因编辑的肿瘤浸润淋巴细胞和t细胞受体工程化t细胞及其在免疫治疗中的应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Rna干渉の方法とrna干渉組成物
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
AU2003290518A1 (en) 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
ATE466933T1 (de) 2005-03-15 2010-05-15 Cellectis I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2013039857A1 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
WO2014131833A1 (en) 2013-02-27 2014-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Gene editing in the oocyte by cas9 nucleases
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
AU2015362618B2 (en) 2014-12-16 2022-01-27 C3J Therapeutics, Inc. Compositions of and methods for in vitro viral genome engineering
GB201515351D0 (en) 2015-08-28 2015-10-14 Cancer Res Technology Antibody
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
GB201621889D0 (en) 2016-12-21 2017-02-01 Autolus Ltd Cell
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
US20210069241A1 (en) * 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
EP3723774A4 (en) 2017-12-15 2021-09-08 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
WO2019165067A1 (en) 2018-02-21 2019-08-29 Bristol-Myers Squibb Company Camk2d antisense oligonucleotides and uses thereof
CA3093919A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3765094A4 (en) * 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
EP3830114A4 (en) 2018-07-31 2022-08-03 Washington University USE OF INTERLEUKIN-7 AND CHIMERA ANTIGEN RECEPTOR (CAR) IMMUNE EFFECTOR CELLS FOR TUMOR TREATMENT
WO2020131862A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
WO2020237040A1 (en) 2019-05-22 2020-11-26 KSQ Therapeutics, Inc. Nr4a super-repressors and methods of use thereof
KR20240028362A (ko) 2021-05-28 2024-03-05 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도

Similar Documents

Publication Publication Date Title
JP7849417B2 (ja) Duocarを用いてがんを処置するための組成物および方法
JP7221213B2 (ja) 多官能性タンパク質
AU2018202294B2 (en) Trifunctional T cell-antigen coupler and methods and uses thereof
JP7584414B2 (ja) 複数の免疫細胞タイプの同時増殖のための方法、関連する組成物および癌免疫療法におけるそれらの使用
Zhang et al. ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma
JP6420776B2 (ja) 免疫療法のためのエンゲージャー細胞
JP2023524047A5 (cg-RX-API-DMAC10.html)
IL279146B2 (en) Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
JP2021521818A (ja) 有効な免疫療法のための抗原−サイトカイン複合体に用いた免疫エフェクター細胞及び分子アダプター
JP2022512968A5 (cg-RX-API-DMAC10.html)
Essand et al. Genetically engineered T cells for the treatment of cancer
Kang et al. Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects
CN118420783A (zh) 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
KR20190039597A (ko) 세포 치료요법을 위한 항상성 활성 사이토킨 수용체
Choi et al. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons
JP2024519335A (ja) がん免疫療法のための投薬レジメン
WO2021057906A1 (zh) 表达il-15的免疫效应细胞
Tesfaye et al. Adoptive cell therapy in treating pediatric solid tumors
KR20240041964A (ko) 입양 면역요법을 위해 기능을 향상시킨 cd3-발현 자연 킬러 세포
Knafler et al. Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy
JP2023506227A5 (cg-RX-API-DMAC10.html)
WO2023051361A1 (zh) 工程化免疫细胞及其用途
KR102562878B1 (ko) 질환 항원이 융합된 단백질 및 이의 용도
Al-Shammari et al. 647. Iraqi Newcastle disease virus virulent strain as cancer antiangiogenic agent
JP2025506515A5 (cg-RX-API-DMAC10.html)